Top Markets
#1 Black Phoenix Black Phoenix +365.58%
#2 Islamic Coin Islamic Coin +158.22%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +55.03%
#5 Akedo Akedo +30.54%
#6 BasedHype BasedHype +29.41%
#7 Acurast Acurast +29.02%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.64%
#9 Cryptopia Cryptopia +21.42%
#10 GoPlus Security GoPlus Security +20.86%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Vaxxinity, Inc. Vaxxinity, Inc.

Vaxxinity, Inc.

VAXX
Rang in Aktien #41693
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-12
Marktkapitalisierung
$12.68K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-99.76%
Land
US
Handel Vaxxinity, Inc. (VAXX)

Kategorie

Healthcare
Operative Marge für Vaxxinity, Inc. (VAXX)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Vaxxinity, Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Vaxxinity, Inc. von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.